Metraipolis › archive › dc_ba65832a73dc

Ofatumumab in refractory anti-muscle-specific tyrosine kinase antibody-positive myasthenia gravis: a case report of successful salvage therapy and mechanistic… — Europe PMC PMID:42358945

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42358945
DOI
10.3389/fimmu.2026.1792262
License (as archived)
solo-consultazione
Archived
2026-10-31T15:05:07.902Z
SHA-256 of the archived text
14e78c3cecb137ea674f61b59cdbea3661fe1a1558b8ba6cb75d5c4f16b744dc
Stable URL of this page
https://metraipolis.com/documento/dc_ba65832a73dc

How to cite

Ofatumumab in refractory anti-muscle-specific tyrosine kinase antibody-positive myasthenia gravis: a case report of successful salvage therapy and mechanistic… — Europe PMC PMID:42358945 — Europe PMC (en), https://europepmc.org/article/MED/42358945 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ba65832a73dc (Metraipolis archive dc_ba65832a73dc, sha256 14e78c3cecb137ea674f61b59cdbea3661fe1a1558b8ba6cb75d5c4f16b744dc)
BibTeX
@misc{dcba65832a73dc,
  title = {Ofatumumab in refractory anti-muscle-specific tyrosine kinase antibody-positive myasthenia gravis: a case report of successful salvage therapy and mechanistic… — Europe PMC PMID:42358945},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42358945},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ba65832a73dc; sha256 14e78c3cecb137ea674f61b59cdbea3661fe1a1558b8ba6cb75d5c4f16b744dc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358945. Agents can read the archived copy with the MCP tool read_document.